With the consistent failure of our expensive pipeline - lackluster clinical results, anemic sales, poor commercial reception.... How long does it take for our Broadway Banker to: 1) cut research - too risky, unproven return 2) have lightbulb come on "hey generic/biosimilars have a very low failure rate" 3) announce "we are downsizing R to reinvest in expanding generics/biosimilars" Is this a 4Q2016 announcement or 1Q2017 ??
